Gene Solutions and Bethesda Medical Provided Free Circulating Tumor DNA(ctDNA) Screening Tests at the 365CPS Bloom with Hope Event

Singapore, March 1st and 2nd, 2025 – Gene Solutions, in proud partnership with Bethesda Medical, a trusted healthcare provider in Singapore for over 20 years, were inspired by the profound resilience of nearly 1,500 cancer fighters and supporters who gathered at the 365 Cancer Prevention Society’s Bloom with Hope event.

Hosted by the 365 Cancer Prevention Society (365CPS), a social service agency dedicated to cancer prevention since 2003, with the tagline “Hope in Every Step”, It’s a recognition of the journey, a journey filled with challenges and triumphs, but ultimately, a journey of hope —a hope to prevent, a hope to fight, and a hope to conquer cancer. On this path, Gene Solutions hopes to accompany and inspire proactive health choices and demonstrate that the road to a healthier future starts with understanding, awareness, and early action to community.

The two-day weekend festival, featuring cancer education, prevention programs, and outdoor activities, provided Gene Solutions and Bethesda Medica with an opportunity to offer free ctDNA cancer screening tests to over 120 participants holding CHAS Blue/Orange government healthcare subsidy cards. This initiative aimed to enhance access to early detection, a big factor in improving cancer outcomes.

Circulating Tumor DNA(ctDNA) Screening Tests at the 365CPS Bloom with Hope Event

Gene Solutions and Bethesda Medica offer free ctDNA cancer screening tests to participants

The event was graced by special guest and honorary patron to 365CPS, Dr Koh Poh Koon, Senior Minister of State, Ministry of Sustainability and the Environment and Ministry of Manpower, who flagged off the day’s festivities amidst a sea of sunflowers, a vibrant emblem associated with joy, strength and optimism.

Recognizing the critical role of early cancer detection, we hope that our humble contributions and commitment will enhance Singapore’s comprehensive awareness campaign for cancer.

“We are deeply committed to making genetic testing accessible to everyone,” said Dr. Christopher Wong – Director, Gene Solutions. ” Our partnership with Bethesda Medical and 365CPS at the Bloom with Hope event allowed us to provide and introduce SPOT-MAS, a non-invasive screening method using ctDNA technology for early cancer detection, to individuals who may not regularly have access to such services.”

Ms. Shantal Chan, Business Development Director from Bethesda added, “Bethesda is proud to collaborate with Gene Solutions and 365CPS in this meaningful initiative. Early detection is crucial in cancer prevention and management, and we are dedicated to supporting community-based efforts that promote health equity.”

The Bloom with Hope event provided a platform for participants to connect, share their experiences, and find support. The free ctDNA cancer screening initiative underscored the event’s commitment to empowering individuals with the tools and resources they need to navigate their cancer journeys.

365 Cancer Prevention Society (365CPS)
The Gene Solutions representative (right) receives a recognition medal from 365CPS

We recognize that our contribution is just one step on the long path, but we carry it with hope, science and passion. We extend our heartfelt thanks to all who joined us in this journey of raising awareness and contributing to the success of the Bloom with Hope event this year and to building a future where hope shines brightly for all.

To learn more about ctDNA screening and its role in early cancer detection, we invite you to watch our informative video: https://www.youtube.com/watch?v=CgbA342VMNg

Gene Solutions x Pioneering Paths: The Science Behind Multi-Cancer Early Detection

About Gene Solutions  Gene Solutions, a pioneering biotech company in Asia, is leading the way in leveraging advanced AI and ctDNA technologies for innovative cancer detection solutions. The company partners with over 4,500 hospitals and clinics across Southeast Asia and boasts a team of approximately 250 biology experts and technicians out of a total of 700 employees. Gene Solutions has published more than 50 peer-reviewed publications and conducted over 50 multi-center studies across the region. The company, recognized for its proprietary research and CAP-accredited laboratories in Singapore and Vietnam, combines multi-dimensional genomics with AI-driven approaches to transform cancer care.

 

 

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More